NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Languages English Remove constraint Languages: English Dates by Range 2000 and later Remove constraint Dates by Range: 2000 and later

Search Results

6101. Gene therapies for sickle cell disease: final evidence report

6102. Resmetirom and obeticholic acid for non-alcoholic steatohepatitis (NASH): final evidence report

6103. Lecanemab for early Alzheimer’s disease: final evidence report

6104. JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

6105. Oral and monoclonal antibody treatments for relapsing forms of multiple sclerosis: effectiveness and value : final evidence report

6106. Tezepelumab for severe asthma: final report

6107. Fezolinetant for moderate to severe vasomotor symptoms associated with menopause: effectiveness and value : final evidence report

6108. Gene therapy for hemophilia B and an update on gene therapy for hemophilia A: effectiveness and value : final evidence report

6109. Special assessment of outpatient treatments for COVID-19: nirmatrelvir/ritonavir (Paxlovid) health-benefit price benchmark update

6110. Anti B-cell maturation antigen CAR T-cell and antibody drug conjugate therapy for heavily pre-treated relapsed and refractory multiple myeloma: final report